Compare YSXT & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YSXT | TELA |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 31.4M |
| IPO Year | 2023 | 2019 |
| Metric | YSXT | TELA |
|---|---|---|
| Price | $1.24 | $1.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $2.08 |
| AVG Volume (30 Days) | 12.8K | ★ 251.2K |
| Earning Date | 07-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $9.24 |
| P/E Ratio | $5.57 | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $0.50 | $0.50 |
| 52 Week High | $3.14 | $1.60 |
| Indicator | YSXT | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 49.26 | 54.61 |
| Support Level | $1.20 | $0.61 |
| Resistance Level | $1.31 | $1.22 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 17.24 | 34.01 |
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services, and Software Development and Information Technology Services. Key revenue is generated from the Auto Insurance Aftermarket Value-added Services segment, which includes four types of value-added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services, and vehicle maintenance and other value-added services.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.